Overview
flowchart TD
clinical_trials_escitalopram_n["Escitalopram for Agitation in Alzheimers Diseas"]
style clinical_trials_escitalopram_n fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_esci_0["Clinical Trial Details"]
clinical_trials_escitalopram_n -->|"includes"| clinical_trials_esci_0
style clinical_trials_esci_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_esci_1["Scientific Rationale"]
clinical_trials_escitalopram_n -->|"includes"| clinical_trials_esci_1
style clinical_trials_esci_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_esci_2["Neuropsychiatric Symptoms in Alzheimers Disease"]
clinical_trials_escitalopram_n -->|"includes"| clinical_trials_esci_2
style clinical_trials_esci_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_esci_3["Serotonergic Hypothesis"]
clinical_trials_escitalopram_n -->|"includes"| clinical_trials_esci_3
style clinical_trials_esci_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_esci_4["Previous Evidence: Citalopram for Agitation"]
clinical_trials_escitalopram_n -->|"includes"| clinical_trials_esci_4
style clinical_trials_esci_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_esci_5["Study Design"]
clinical_trials_escitalopram_n -->|"includes"| clinical_trials_esci_5
style clinical_trials_esci_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Escitalopram for Agitation in Alzheimer's Disease (S-CitAD) is a Phase 3 randomized, quadruple-blind, placebo-controlled clinical trial evaluating the efficacy and safety of escitalopram for the treatment of agitation in patients with [Alzheimer's disease](/diseases/alzheimers-disease). Agitation is one of the most distressing neuropsychiatric symptoms of dementia, affecting up to 70% of [Alzheimer's disease](/diseases/alzheimers-disease) patients at some point during their illness and representing a leading cause of nursing home placement["@lyketsos2018"].
This trial builds upon earlier work with citalopram — the CMS (CitAD) study demonstrated that citalopram reduced agitation versus placebo but was limited by QTc prolongation concerns — and aims to establish whether the more selective SSRI escitalopram can provide efficacy with an improved safety profile["@bCMA"][@porsteinsdottir2009].
Clinical Trial Details
| Attribute | Value |
|-----------|-------|
| NCT Number | NCT03108846 |
| Official Title | Escitalopram for Agitation in Alzheimer's Disease |
| Phase | Phase 3 |
| Status | Active, not recruiting (Primary completion: April 2024; Anticipated completion: May 2025) |
| Enrollment | 187 participants (actual) |
| Allocation | Randomized |
| Masking | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Intervention | Escitalopram 5-15 mg/day (target 15 mg/day) vs. placebo |
| Sponsor | Johns Hopkins Bloomberg School of Public Health Center for Clinical Trials |
| Funder | National Institute on Aging (NIA) — R01AG052510 |
| Study Chair | Constantine Lyketsos, MD, MHS (Johns Hopkins University) |
| Registration | ClinicalTrials.gov |
Scientific Rationale
Neuropsychiatric Symptoms in Alzheimer's Disease
Agitation in [Alzheimer's disease](/diseases/alzheimers-disease) represents a significant clinical challenge with multidimensional origins[@zhu2020]:
Neurobiological basis: Serotonergic dysfunction in the frontal cortex and basal ganglia contributes to impulsivity, aggression, and agitation[@cunningham2019]
Disease progression: Agitation correlates with neurodegeneration in circuits governing emotional regulation and impulse control
Environmental triggers: Changes in routine, unfamiliar settings, or excessive stimulation can precipitate agitation
Communication difficulties: Frustration from progressive language impairment manifests as agitationThe prevalence of agitation increases with disease severity, affecting approximately 30% of patients with mild [Alzheimer's disease](/diseases/alzheimers-disease), 50% with moderate disease, and 70% with severe disease[@bergh2021].
Serotonergic Hypothesis
The rationale for SSRIs in Alzheimer's agitation rests on the serotonergic system's role in mood regulation and impulse control[@hindler2021]:
Serotonin (5-HT) dysfunction is documented in Alzheimer's disease brains, with reduced 5-HT2A receptor binding in frontal regions
SSRIs enhance serotonergic transmission by blocking serotonin reuptake, improving emotional regulation
Escitalopram is the most selective SSRI available, with high affinity for the serotonin transporter (SERT) and minimal off-target effects
Escitalopram lacks significant cardiotoxicity unlike citalopram (which blocks cardiac potassium channels causing QTc prolongation)Previous Evidence: Citalopram for Agitation
The Citalopram in Alzheimer's Disease (CitAD) study established the proof-of-concept for serotonergic treatment of agitation[@bCMA]:
- Design: 8-week, randomized, double-blind, placebo-controlled
- Participants: 186 nursing home residents with probable Alzheimer's disease and agitation
- Intervention: Citalopram 10-30 mg/day vs. placebo
- Results: Citalopram significantly improved agitation on the Neurobehavioral Rating Scale (NBRS-A) vs. placebo (p=0.03)
- Limitation: QTc prolongation (mean increase 18 ms) raised cardiac safety concerns
This trial extends the CitAD approach with escitalopram, leveraging its superior selectivity and anticipated improved cardiac safety profile.
Study Design
Intervention
Escitalopram (Lexapro) is administered at 5-15 mg/day, with a target dose of 15 mg/day if tolerated[@nct03108846]. The drug is provided as 1-3 capsules, each containing 5 mg escitalopram, taken once daily in the morning. The placebo arm receives identical-appearing capsules without active drug.
Dose titration follows a conservative schedule:
- Week 1: 5 mg/day (one capsule)
- Week 2 onward: 10 mg/day (two capsules) if tolerated
- Week 3+: 15 mg/day (three capsules) if no significant adverse effects
Outcome Measures
Primary Outcome[@nct03108846]:
- modified Alzheimer's Disease Cooperative Study — Clinical Global Impression of Change (mADCS-CGIC)
- Timeframe: After 12 weeks of treatment
- The mADCS-CGIC is a validated clinician-rated instrument assessing overall change in agitation from baseline
Secondary Outcomes:
The trial includes additional efficacy and safety measures covering cognitive function, functional status, caregiver burden, and adverse events. Specific secondary endpoints assess:
- Change in agitation frequency and severity on standardized scales
- Cognitive outcomes (MMSE, other neuropsychological tests)
- Caregiver burden measures
- Safety and tolerability (adverse events, ECG changes, laboratory abnormalities)
Eligibility Criteria
Inclusion Criteria[@nct03108846]:
- Clinical diagnosis of probable [Alzheimer's disease](/diseases/alzheimers-disease) per NIA/AA 2011 criteria
- Mini-Mental State Examination Telephone (MMSET) score of 3-20 inclusive
- Meets International Psychogeriatric Association (IPA) provisional criteria for agitation in cognitive disorders
- Clinically significant agitation/aggression as assessed by NPI (frequency "Very frequently" or "Frequently" with "Moderate" or "Marked" severity)
- Provision of informed consent by both caregiver and participant (or surrogate consent with participant assent)
- Availability of a caregiver who spends at least several hours per week with the participant
- Stable dosing of antipsychotics for agitation or psychosis (if used) for at least 7 days
- Clinical judgment that a medication for agitation is appropriate
Exclusion Criteria[@nct03108846]:
- Major depressive episode (MDE) within the past 90 days per DSM-V
- Presence of another brain disease fully explaining the dementia
- Residence in skilled nursing or long-term acute care facility
- Contraindication to escitalopram (recent MAOI use, hypersensitivity)
- Prior failed treatment with citalopram or escitalopram for agitation
- Indication for psychiatric hospitalization or acute suicidality
- Recent changes in antipsychotics, anticonvulsants, or psychosis medications (within 7 days)
- Abnormal QTc interval (>450 ms for men, >470 ms for women)
- Severely reduced renal function (GFR <30 mL/min) or hepatic dysfunction (within 30 days)
- Current treatment with certain antidepressants, benzodiazepines (other than lorazepam), or psychostimulants
- Recent use of medical marijuana (within 14 days)
- Current participation in another clinical trial
- Significant communicative impairments or any condition making enrollment medically inappropriate
Sites and Recruitment
The trial is conducted at 35+ clinical sites across the United States and Canada, including leading academic medical centers[@nct03108846]:
United States sites:
- Banner Sun Health Research Institute (Sun City, Arizona)
- UCLA/VA Greater Los Angeles Healthcare System (Los Angeles, California)
- USC Keck School of Medicine (Los Angeles, California)
- Miami Jewish Health Systems (Miami, Florida)
- Johns Hopkins Bayview (Baltimore, Maryland)
- Columbia University (New York, New York)
- University of Pittsburgh (Pittsburgh, Pennsylvania)
- And additional sites in Arkansas, Kansas, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, South Carolina, Texas, Virginia, and Washington
Canadian sites:
- University of Calgary and Foothills Medical Centre (Calgary, Alberta)
- Lawson Health Research Institute (London, Ontario)
- Sunnybrook Health Sciences Centre, Unity Health, Centre for Addiction and Mental Health (Toronto, Ontario)
- Ontario Shores Centre for Mental Health Sciences (Whitby, Ontario)
Clinical Significance
Impact of Agitation in Alzheimer's Disease
Agitation is associated with profound clinical consequences[@kales2014][@seifu2024]:
Accelerated disease progression: Agitated patients show faster cognitive decline
Increased mortality: Dementia patients with agitation have significantly higher mortality rates
Caregiver burden: Agitation is the leading cause of caregiver burnout and decisions to place patients in institutional care
Healthcare costs: Managing agitation accounts for a disproportionate share of dementia-related healthcare expenditure
Quality of life: Both patient and caregiver quality of life are severely impactedUnmet Medical Need
Despite the high prevalence of agitation in [Alzheimer's disease](/diseases/alzheimers-disease), treatment options remain limited[@seifu2024]:
| Treatment | Efficacy | Limitations |
|-----------|----------|-------------|
| Antipsychotics | Modest | Black box warnings, increased mortality, cognitive effects |
| Citalopram | Moderate | QTc prolongation, cardiac risks |
| Non-pharmacological | Variable | Difficult to implement in advanced dementia |
| Other SSRIs | Limited evidence | Escitalopram specifically understudied |
Why Escitalopram?
Escitalopram offers potential advantages over existing treatments[@hindler2021][@lyketsos2013]:
High selectivity: Greater SERT affinity than citalopram, with minimal interaction with other neurotransmitter systems
Favorable cardiac profile: Unlike citalopram, escitalopram does not significantly block the hERG potassium channel responsible for QTc prolongation
Tolerability: Lower rates of discontinuation compared to other antidepressants in elderly populations
Established safety: Well-characterized safety profile in older adults with depression
Bidirectional benefit: Potential improvement in both agitation and comorbid depressive symptomsNon-Pharmacological Context
Non-pharmacological interventions remain first-line for agitation in dementia[@banerjee2011][@miller2023]:
- Person-centered care: Tailoring care to individual preferences and needs
- Environmental modification: Reducing noise, clutter, and overstimulation
- Communication training: Educating caregivers on effective communication strategies
- Structured activities: Engaging patients in meaningful, calming activities
- Validation therapy: Acknowledging and responding to underlying emotional needs
This trial does not exclude patients receiving non-pharmacological interventions, recognizing the complementary role of both approaches.
Expected Outcomes and Results
The trial's primary completion in April 2024 with results submitted to ClinicalTrials.gov in February 2026 suggests the following outcomes are anticipated:
Efficacy expectations:
- Escitalopram will demonstrate superiority over placebo on the mADCS-CGIC at 12 weeks
- Secondary agitation scales (NPI agitation subscale, Cohen-Mansfield Agitation Inventory) will show significant improvement
- Improvement will be clinically meaningful (defined as ≥1 point change on mADCS-CGIC)
Safety expectations:
- Escitalopram will show significantly less QTc prolongation than citalopram at equivalent doses
- Discontinuation rates will be comparable to or lower than placebo
- No significant cognitive deterioration during treatment
Future Directions
Regardless of trial outcome, NCT03108846 will inform future research in several directions:
Biomarker development: Identification of predictors of treatment response (serotonergic polymorphisms, neuroimaging markers)
Combination approaches: Evaluating escitalopram combined with non-pharmacological interventions
Long-term extension: Assessment of sustained efficacy and safety beyond 12 weeks
Subgroup analyses: Response by agitation subtype (physical vs. verbal), disease severity, genetic backgroundRelated Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Neuropsychiatric Symptoms in Alzheimer's Disease](/mechanisms/neuropsychiatric-symptoms-ad)
- [Depression in Neurodegeneration](/mechanisms/depression-neurodegeneration)
- [Biomarkers for Agitation in Dementia](/biomarkers/neuropsychiatric-symptoms-biomarkers)
- [Citalopram in Alzheimer's Disease (CitAD)](/clinical-trials/citalopram-alzheimers-citad)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
External Links
- [ClinicalTrials.gov: NCT03108846](https://clinicaltrials.gov/ct2/show/NCT03108846)
- [Johns Hopkins Memory and Aging Project](https://www.hopkinsmedicine.org/psychiatry/research/special-programs/memory)
- [NIA-funded Alzheimer's Disease Research Centers](https://www.nia.nih.gov/health-care/alzheimers-disease-research-centers)